EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Human Pharmacokinetic Prediction of Antibody‐Drug Conjugates Using Human FcRn Transgenic Mice

Keitaro Nakagawa iD, Kenta Haraya iD

Clinical and Translational Science · 2026-08 · 19 (8)

DOI: 10.1111/cts.70692 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Science, online erschienen am 31.07.2026. Verfasst von Keitaro Nakagawa und 1 weiteren Autor:innen. Beteiligte Einrichtung: Research Division, Chugai Pharmaceutical Co. Ltd, Yokohama, Japan. Hauptthemen laut MEDLINE: Receptors, Fc, Histocompatibility Antigens Class I, Immunoconjugates. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antibody‐drug conjugates (ADCs) have progressed significantly in recent years, particularly in the oncology field. However, predicting human pharmacokinetics (PK) of ADCs in the early stages of drug development remains challenging. Human neonatal Fc receptor (FcRn) transgenic mice have been established as a reliable pre‐clinical PK model for predicting human PK profiles of antibody‐based therapeutics. In this study, we investigated the applicability of human FcRn transgenic mice for predicting the human PK of ADCs in a pre‐clinical setting. Eight FDA‐approved ADCs were administered to human FcRn transgenic mice, and PK parameters were calculated using two‐compartment model analysis. The clearance (CL) values of total ADCs in human FcRn transgenic mice showed a strong correlation with human CL ( R 2 = 0.888). Single‐species allometric scaling using data from human FcRn transgenic mice indicated an optimal exponent of 1.0 for predicting human CL, with 87.5% of ADCs falling within twofold of the human CL. These findings indicate that allometric scaling from human FcRn transgenic mice serves as a promising translational tool for predicting human CL of ADCs from the early development stage.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, FcHistocompatibility Antigens Class IImmunoconjugatesAnimalsMice, TransgenicHumansMiceFemaleModels, Biological

Stichwörter der Autor:innen

FcRnallometric scalingantibody‐drug conjugatepharmacokinetics

Substanzen

Receptors, FcHistocompatibility Antigens Class IFc receptor, neonatalImmunoconjugates

Autor:innen und Institutionen

  • Research Division, Chugai Pharmaceutical Co. Ltd, Yokohama, Japan.

ORCID-Profile: Keitaro Nakagawa, Kenta Haraya

Zitieren

APA

Nakagawa, K., & Haraya, K. (2026). Human Pharmacokinetic Prediction of Antibody‐Drug Conjugates Using Human FcRn Transgenic Mice. Clinical and Translational Science, 19(8). https://doi.org/10.1111/cts.70692

Vancouver

Nakagawa K, Haraya K. Human Pharmacokinetic Prediction of Antibody‐Drug Conjugates Using Human FcRn Transgenic Mice. Clinical and Translational Science. 2026;19(8). doi:10.1111/cts.70692

BibTeX
@article{Nakagawa2026,
  author = {Nakagawa, Keitaro and Haraya, Kenta},
  title = {Human Pharmacokinetic Prediction of Antibody‐Drug Conjugates Using Human FcRn Transgenic Mice},
  journal = {Clinical and Translational Science},
  year = {2026},
  volume = {19},
  number = {8},
  doi = {10.1111/cts.70692}
}
Kostenlos starten →